0K1R logo

Viridian Therapeutics LSE:0K1R Stock Report

Last Price

US$12.77

Market Cap

US$839.3m

7D

6.1%

1Y

-54.4%

Updated

14 Jun, 2024

Data

Company Financials +

Viridian Therapeutics, Inc.

LSE:0K1R Stock Report

Market Cap: US$839.3m

Viridian Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Viridian Therapeutics
Historical stock prices
Current Share PriceUS$12.77
52 Week HighUS$26.54
52 Week LowUS$10.98
Beta1.06
1 Month Change-11.65%
3 Month Change-25.70%
1 Year Change-54.39%
3 Year Changen/a
5 Year Changen/a
Change since IPO-90.08%

Recent News & Updates

Recent updates

Shareholder Returns

0K1RGB BiotechsGB Market
7D6.1%-3.7%-1.8%
1Y-54.4%-26.9%4.2%

Return vs Industry: 0K1R underperformed the UK Biotechs industry which returned -26.9% over the past year.

Return vs Market: 0K1R underperformed the UK Market which returned 4.2% over the past year.

Price Volatility

Is 0K1R's price volatile compared to industry and market?
0K1R volatility
0K1R Average Weekly Movement7.7%
Biotechs Industry Average Movement6.0%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.8%

Stable Share Price: 0K1R's share price has been volatile over the past 3 months.

Volatility Over Time: 0K1R's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
201094Steve Mahoneywww.viridiantherapeutics.com

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease.

Viridian Therapeutics, Inc. Fundamentals Summary

How do Viridian Therapeutics's earnings and revenue compare to its market cap?
0K1R fundamental statistics
Market capUS$839.27m
Earnings (TTM)-US$218.12m
Revenue (TTM)US$288.00k

2,914x

P/S Ratio

-3.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0K1R income statement (TTM)
RevenueUS$288.00k
Cost of RevenueUS$149.97m
Gross Profit-US$149.68m
Other ExpensesUS$68.44m
Earnings-US$218.12m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.42
Gross Margin-51,972.57%
Net Profit Margin-75,737.85%
Debt/Equity Ratio3.5%

How did 0K1R perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.